Bio-Techne completes $257M investment for 20% stake in Wilson Wolf; future buyout potential $1B

BIO-TECHNE Corp

$257M investment gives Bio-Techne 20% ownership of Wilson Wolf Manufacturing.
Investment triggered by Wilson Wolf achieving $55M trailing twelve-month EBITDA.
Bio-Techne has right to acquire remaining 80% for $1B if Wilson Wolf reaches $226M revenue or $136M EBITDA.
If milestone not met by Dec 31, 2027, acquisition price ~4.4x trailing twelve-month revenue.
Wilson Wolf develops G-Rex cell production technology for cell and gene therapy; used by over 800 CGT market participants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.